Understanding the impact of systemic psoriasis treatment on E-selectin and VCAM-1 serum levels will enable the selection of the appropriate therapy for both cardiovascular disease and skin lesions as coexisting conditions. This evidence concerns the gene VCAM1 and cardiovascular disorder.